Trial Profile

ACTIVATE

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2012

At a glance

  • Drugs Rindopepimut (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Acronyms ACT-II; ACTIVATE
  • Most Recent Events

    • 15 Nov 2012 3-Year survival data will be presented at the Society of Neuro-Oncology's 17th Annual Scientific Meeting and Education Day, according to a Celldex Therapeutics media release.
    • 05 Nov 2012 Updated survival data will be presented at the Society of Neuro-Oncology's 17th Annual Scientific Meeting and Education Day according to a Celldex Therapeutics media release.
    • 04 Jan 2012 Status changed from active, no longer recruiting to completed, according to a Celldex media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top